Viatris sees bigger future in biosimilars — and a bigger return
March 01, 2021 at 11:04 AM EST
Viatris, and Mylan before it, saw biosimilars as a way to grow its business and create a differentiation among its competitors.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|